查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1610267

肺炎治疗药物市场：按药物类别、肺炎类型、年龄层、分销管道划分 - 全球预测 2025-2030

Pneumonia Therapeutics Market by Drug Class, Pneumonia Type (Community-acquired pneumonia, Hospital-acquired pneumonia, Ventilator-associated pneumonia ), Age Group, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肺炎药物市值为153.4亿美元，预计到2024年将达到166.4亿美元，复合年增长率为8.93%，到2030年将达到279.3亿美元。

肺炎治疗市场包括旨在对抗肺炎的多种治疗和预防措施，肺炎是一种影响肺部且主要由感染疾病引起的发炎疾病。该系列包括抗生素、疫苗和其他旨在减轻症状和根除感染的治疗方法。肺炎的高发病率和死亡率凸显了对有效治疗的需求，特别是在幼儿、老年人和免疫力缺乏等弱势群体中。肺炎药物不仅用于治疗，还用于透过疫苗接种进行预防，凸显了预防医学在医疗保健系统中的重要性。最终用途主要集中在医院、诊所和居家医疗机构，重点关注治疗的可近性和有效性，以减少住院时间并改善患者的治疗效果。影响该市场的关键成长要素包括人口老化导致的肺炎发病率增加和慢性病的流行，从而对先进治疗解决方案产生了持续的需求。此外，研究技术的进步和医疗保健支出的增加正在创造重要的创新机会，特别是在开发新型疫苗和抗生素疗法方面，重点是克服抗生素抗药性。然而，市场开拓受到高昂的治疗开发成本、严格的监管核准以及疫苗犹豫不决的新威胁等因素的阻碍。潜在的创新领域包括探索个人化医疗方法和利用人工智慧来更好地管理患者。对新药物传输系统的研究和增强现有疫苗以涵盖更广泛的病原体也可能推动市场进步。透过这种方式，公司可以利用与生技公司的伙伴关係关係，投资于突破性治疗方法的研发，并专注于对成本效益市场需求较高的新兴市场进行扩张。

主要市场统计
基准年[2023] 153.4亿美元
预计年份 [2024] 166.4亿美元
预测年份 [2030] 279.3亿美元
复合年增长率（%） 8.93%

市场动态：快速发展的肺炎药物市场的关键市场洞察

供需的动态交互作用正在改变肺炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 肺炎盛行率不断上升，需要有效的治疗
    • 大量投入肺炎治疗药物研发
    • 增加具有成本效益的非专利肺炎治疗方法
  • 市场限制因素
    • 肺炎治疗时间延长
  • 市场机会
    • 新技术改善肺炎诊断和治疗
    • 越来越重视个人化医疗以生产高效药物
  • 市场挑战
    • 某些肺炎治疗可能产生的副作用

波特五力：驾驭肺炎药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肺炎药物市场的外部影响

外部宏观环境因素对肺炎治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肺炎治疗药物市场的竞争状况

对肺炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵性肺炎药物市场供应商的绩效评估

FPNV定位矩阵是评估肺炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘肺炎治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肺炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肺炎的传播和有效治疗的需要
      • 大量投入肺炎治疗药物研发
      • 提高非专利成本效益的肺炎通用治疗方法的可用性
    • 抑制因素
      • 肺炎治疗时间延长
    • 机会
      • 新技术改善肺炎诊断和治疗
      • 个人化医疗对于高效药物生产变得越来越重要
    • 任务
      • 某些肺炎治疗的潜在副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的肺炎治疗药物市场

  • 抗生素
  • 抗真菌药物
  • 抗病毒药物

第七章 依肺炎类型分類的肺炎治疗药物市场

  • 社区型肺炎（CAP）
  • 院内获得性肺炎 (HAP)
  • 人工呼吸器相关性肺炎（VAP）

第八章肺炎治疗药物市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第九章肺炎治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十章 北美及南美肺炎治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太肺炎药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲肺炎药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Allergan plc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus UK Limited by CSL Limited
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma
  • Zydus Healthcare Limited
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market was valued at USD 15.34 billion in 2023, expected to reach USD 16.64 billion in 2024, and is projected to grow at a CAGR of 8.93%, to USD 27.93 billion by 2030.

The pneumonia therapeutics market encompasses a wide array of medical treatments and preventative measures designed to combat pneumonia, an inflammatory condition affecting the lungs primarily caused by infections. This scope includes antibiotics, vaccines, and other treatment modalities aimed at alleviating symptoms and eradicating infection. The necessity for effective pneumonia therapeutics is underscored by the disease's significant morbidity and mortality rates, particularly among vulnerable populations such as young children, the elderly, and immunocompromised individuals. Applications of pneumonia therapeutics extend beyond treatment to encompass prevention through vaccination, underlying the importance of preventative care in healthcare systems. End-use is primarily concentrated in hospitals, clinics, and home healthcare settings, where the focus is on accessibility and efficacy of treatments to reduce hospital stays and improve patient outcomes. Key growth factors influencing this market include rising incidence rates of pneumonia due to aging populations and the increasing prevalence of chronic diseases, creating a sustained demand for advanced therapeutic solutions. Additionally, developments in research technology and increased healthcare spending present substantial opportunities for innovation, particularly in the development of novel vaccines and antibiotic therapies, with an emphasis on overcoming antibiotic resistance. However, market growth is constrained by factors such as high costs of treatment development, stringent regulatory approvals, and the emerging threat of vaccine hesitancy. Potential areas for innovation include exploring personalized medicine approaches and leveraging AI for better patient management. Emphasizing the research of new drug delivery systems and enhancing existing vaccines to cover a broader spectrum of pathogens could also stimulate market advances. Thus, businesses can capitalize on partnerships with biotech firms, invest in R&D for breakthrough therapies, and focus on expanding their reach in emerging markets where the demand for cost-effective pneumonia therapeutics is high, all within a competitive yet promising market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 15.34 billion
Estimated Year [2024] USD 16.64 billion
Forecast Year [2030] USD 27.93 billion
CAGR (%) 8.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumonia Therapeutics Market

The Pneumonia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of pneumonia and the need for efficient treatment
    • Significant investments in research & development of pneumonia-therapeutics
    • Increasing availability of generic and cost-effective pneumonia drugs
  • Market Restraints
    • Prolonged treatment duration for pneumonia
  • Market Opportunities
    • Emerging technologies to improve diagnosis and treatment of pneumonia
    • Growing emphasis on personalized medicine for the production of efficient drugs
  • Market Challenges
    • Potential side effects associated with certain pneumonia therapies

Porter's Five Forces: A Strategic Tool for Navigating the Pneumonia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumonia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumonia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumonia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumonia Therapeutics Market

A detailed market share analysis in the Pneumonia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumonia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumonia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumonia Therapeutics Market

A strategic analysis of the Pneumonia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumonia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biobrick Pharma, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lincoln Pharmaceuticals Ltd., Lupin Pharmaceuticals, Inc., Mankind Pharma Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Seqirus UK Limited by CSL Limited, Serum Institute of India, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Wellona Pharma, and Zydus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Pneumonia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
  • Based on Pneumonia Type, market is studied across Community-acquired pneumonia (CAP), Hospital-acquired pneumonia (HAP), and Ventilator-associated pneumonia (VAP).
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatrics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pneumonia and the need for efficient treatment
      • 5.1.1.2. Significant investments in research & development of pneumonia-therapeutics
      • 5.1.1.3. Increasing availability of generic and cost-effective pneumonia drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Prolonged treatment duration for pneumonia
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging technologies to improve diagnosis and treatment of pneumonia
      • 5.1.3.2. Growing emphasis on personalized medicine for the production of efficient drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects associated with certain pneumonia therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumonia Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antibacterial Drugs
  • 6.3. Antifungal Drugs
  • 6.4. Antiviral Drugs

7. Pneumonia Therapeutics Market, by Pneumonia Type

  • 7.1. Introduction
  • 7.2. Community-acquired pneumonia (CAP)
  • 7.3. Hospital-acquired pneumonia (HAP)
  • 7.4. Ventilator-associated pneumonia (VAP)

8. Pneumonia Therapeutics Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatrics

9. Pneumonia Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Pneumonia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumonia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumonia Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan plc
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. Bayer AG
  • 6. Biobrick Pharma
  • 7. Cipla Limited
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Hikma Pharmaceuticals PLC
  • 13. Lincoln Pharmaceuticals Ltd.
  • 14. Lupin Pharmaceuticals, Inc.
  • 15. Mankind Pharma Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Seqirus UK Limited by CSL Limited
  • 21. Serum Institute of India
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Wellona Pharma
  • 26. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. PNEUMONIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMONIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PNEUMONIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBACTERIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY-ACQUIRED PNEUMONIA (CAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA (HAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR-ASSOCIATED PNEUMONIA (VAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023